Your Health, We Care
Drug interactions may occur when revumenib is used concomitantly with the following medications:
Strong CYP3A4 inhibitors: The dosage of revumenib needs to be reduced.
Strong or moderate CYP3A4 inducers: Concomitant use with revumenib should be avoided.
Medications that prolong the QTc interval: Concomitant use with revumenib should be avoided. If concomitant use is unavoidable, electrocardiogram monitoring should be performed prior to the initiation of concomitant use, during the course of concomitant use, and when clinically indicated. If the QTc interval exceeds 480 milliseconds, revumenib should be suspended. Treatment with revumenib may be resumed after the QTc interval returns to ≤ 480 milliseconds.
FDA，2025.10
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor···【more】
Release date：2026-01-29Recommended：9
Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhib···【more】
Release date：2026-01-29Recommended：11
